Dr. Tobias Arkenau

Dr. Tobias Arkenau is a world-renowned expert in the clinical and translational development of new cancer treatments. He has over 20 years of experience and has worked on more than 300 oncology trials at all stages of development. Dr. Arkenau has a broad range of experience in treating patients with gastrointestinal cancers (bowel, stomach, pancreas, biliary tree, liver) and skin cancers using various treatments, such as immunotherapy, targeted therapy, and chemotherapies.

Dr. Arkenau's career began in 2000 as an Assistant Doctor at Hospital St. Joseph-Stift Bremen in Germany. He then moved to the UK to become a Senior Clinical Research Fellow in Oncology Drug Development at the Royal Marsden Hospital in 2005. He held the position until 2008, when he became a Team Leader in Clinical Drug Development at the University of New South Wales in Australia. He then moved back to the UK in 2010 to become the Executive Medical Director at the Sarah Cannon Research Institute, a role he held until 2022.

In addition to his industry roles, Dr. Arkenau has been an Honorary Professor at University College London, Cancer Institute since 2011. He has also been a Clinical Lead in the Oncology Service Line at HCA International from 2015 to 2022. In 2022, he became the CMO and Global Head of Drug Development at Ellipses Pharma.

Dr. Arkenau has published over 200 articles in international peer-reviewed journals, including Lancet, J Clin Oncol, Clin Cancer Res, and Annals of Oncology. He is also an Associate Editor of the World Journal of Cancer Research and a Contributing Associate Editor-in-Chief of the World Journal of Gastroenterology.

Dr. Arkenau is affiliated with the German Cancer Society, American Society of Clinical Oncology, American Association for Cancer Research, and European Society for Medical Oncology. He regularly consults with international patients and is considered a global authority in his field.